Gregor Diagnostics Inc., a molecular diagnostics company developing a groundbreaking new screening test for prostate cancer, and the Wisconsin Alumni Research Foundation (WARF), the private non-profit patenting and licensing organization for the University of Wisconsin-Madison, today announced that they have entered into an exclusive license agreement. The agreement grants exclusive rights to Gregor for intellectual property covering biomarkers that Gregor anticipates developing and commercializing as part of a unique screening test for the detection and characterization of prostate cancer from seminal fluid.

“Prostate cancer is the third leading cause of cancer death in American men,” said Erik Iverson, WARF’s Managing Director.  “When detected early, prostate cancer has a far better chance of successful treatment.  WARF is delighted to partner with Gregor Diagnostics on advancing this technology that will surely positively impact opportunities for early diagnosis and treatment of prostate cancer.”

The agreement covers a panel of DNA methylation biomarkers that can inform treatment. The biomarkers were discovered in the lab of Dr. David Jarrard at the University of Wisconsin Carbone Cancer Center. The agreement also covers methods for the detection of the AMACR protein that were discovered by Dr. Jarrard’s lab in collaboration with Dr. Wei Huang at the University of Wisconsin-Madison. These technologies, in addition to others yet to be disclosed, provide a base for Gregor to develop a new prostate cancer screening test to detect prostate cancer in its earliest stages of development and to aid in the differentiation of slow-growing or aggressive disease. Read the full story here.